Peer Reviewed

1

Document Type

Article

Publication Date

11-2014

Keywords

Down syndrome, Intellectual disability, Alzheimer’s disease, Dementia, Magnetic resonance spectroscopy, H MRS, Hippocampus, Glutamate-glutamine (Glx)

Funder/Sponsor

South London and Maudsley National Health Service (NHS) Foundation Trust (National Division), the Baily Thomas Charitable Fund, the Sackler Institute for Neurodevelopmental Translational Research, the NIHR Biomedical Research Centre and NIHR Biomedical Research Unit for Dementia at the South London and Maudsley NHS Foundation Trust, and Institute of Psychiatry, King’s College London.

Comments

The original article is available at www.biomedcentral.com

Abstract

Background: Down syndrome (DS), or trisomy 21, is one of the most common autosomal mutations. People with DS have intellectual disability (ID) and are at significantly increased risk of developing Alzheimer’s disease (AD). The biological associates of both ID and AD in DS are poorly understood, but glutamate has been proposed to play a key role. In non-DS populations, glutamate is essential to learning and memory and glutamate-mediated excitotoxicity has been implicated in AD. However, the concentration of hippocampal glutamate in DS individuals with and without dementia has not previously been directly investigated. Proton magnetic resonance spectroscopy (1H MRS) can be used to measure in vivo the concentrations of glutamate-glutamine (Glx). The objective of the current study was to examine the hippocampal Glx concentration in non-demented DS (DS-) and demented DS (DS+) individuals.

Methods: We examined 46 adults with DS (35 without dementia and 11 with dementia) and 39 healthy controls (HC) using 1H MRS and measured their hippocampal Glx concentrations.

Results: There was no significant difference in the hippocampal Glx concentration between DS+ and DS-, or between either of the DS groups and the healthy controls. Also, within DS, there was no significant correlation between hippocampal Glx concentration and measures of overall cognitive ability. Last, a sample size calculation based on the effect sizes from this study showed that it would have required 6,257 participants to provide 80% power to detect a significant difference between the groups which would indicate that there is a very low likelihood of a type 2 error accounting for the findings in this study.

Conclusions: Individuals with DS do not have clinically detectable differences in hippocampal Glx concentration. Other pathophysiological processes likely account for ID and AD in people with DS.

Disciplines

Medicine and Health Sciences | Psychiatry and Psychology

Citation

Giles MY Tan, Felix Beacher, Eileen Daly, Jamie Horder, Verinder Prasher, Maria-Luisa Hanney, Robin Morris, Simon Lovestone, Kieran C Murphy, Andrew Simmons, Declan GM Murphy. Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy (1H MRS) Journal of Neurodevelomental Disorders. 2014;6:42

PubMed ID

25937842

DOI Link

10.1186/1866-1955-6-42

Share

COinS